To hear about similar clinical trials, please enter your email below
Trial Title:
Study on AUNIP as a Novel Tumor Marker for Cervical Cancer
NCT ID:
NCT06118463
Condition:
Cervical Cancer
Conditions: Official terms:
Uterine Cervical Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
Detection of serum AUNIP expression
Description:
The experiment is carried out according to the ELISA kit instructions, and the absorbance
optic density (OD) value of the enzyme labeler at 450 nm is read. The protein
concentration of AUNIP in the serum sample is calculated according to the standard curve.
Arm group label:
Healthy control group
Arm group label:
study group
Summary:
To detect the expression of AUNIP in cervical cancer serum, and to clarify its diagnostic
and prognostic value.
Detailed description:
Blood of all study participants of cervical cancer patients are collected to detect the
expression of AUNIP, analyze the statistical correlation between the expression of
cervical cancer AUNIP and clinicopathological parameters of patients, and preliminarily
understand the expression of AUNIP in cervical cancer tumor tissues and its clinical
diagnostic and progniostic value.
Criteria for eligibility:
Study pop:
In this study, 150 patients with cervical cancer in the First Affiliated Hospital of
Shandong First Medical University (Shandong Qianfoshan Hospital) are selected as the
study group. 150 healthy women are taken as control group during the same period.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
Study group inclusion criteria:
- Women aged 20-60
- There is a definite pathological diagnosis of cervical cancer
Healthy control group:
- Women aged 20-60
- No tumors in the uterus or other parts of the body
- No inflammatory disease
- Blood routine and blood biochemical tests are normal
Exclusion Criteria:
Exclusion criteria of the study group:
- There are other lesions in the uterus and uterine adnexa
Exclusion criteria of healthy control group:
- Pregnant, lactating or menarche women
- Women who are undergoing human papillomavirus (HPV) vaccination
Gender:
Female
Minimum age:
20 Years
Maximum age:
60 Years
Healthy volunteers:
Accepts Healthy Volunteers
Start date:
January 1, 2024
Completion date:
January 1, 2029
Lead sponsor:
Agency:
Lin Yuan
Agency class:
Other
Source:
Qianfoshan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06118463
